AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or ...

High blood pressure, or hypertension, often goes unnoticed but can lead to severe health issues like heart attack and stroke.

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

Atrioventricular interval modulation is being studied for patients with uncontrolled hypertension. Could the new technology ...

Other standout performers included cycling, which had stronger effects than walking in both pressure types. Walking, though ...

Green tea can help lower blood pressure when consumed regularly. Learn how often and how much to drink to reap the blood ...

Patients in a late-stage trial received one of two different doses of Baxdrostat or a placebo drug once a day, the drugmaker ...

AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

The American Heart Association currently defines exaggerated systolic blood pressure response to exercise (ESBPR) using sex-specific thresholds—≥210 mmHg for men and ≥190 mmHg for women. These cutoffs ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

Bedtime dosing of antihypertensive medication provided better control of nocturnal blood pressure and improved circadian ...